Skip to main content
SpringerLink
Log in

Antiviral agents: An update—Part I

  • Symposium on Infections
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Whitly RJ, Alford CA: Developmental aspects of selected antiviral chemotherapeutic agents. Ann Rev Microbiol 32:285, 1978

    Article  Google Scholar 

  2. Hoffmann CE, Neumayer EM, Haff RF, Goldsby RA: Mode of action of the antiviral activity of amantadine in tissue culture. J Bacteriol 90:623, 1965

    PubMed  CAS  Google Scholar 

  3. Kato M, Eggers HJ: Inhibition of uncoating of fowl plaque virus by 1-adamantanamine hydrochloride. Virology 37:632, 1969

    Article  PubMed  CAS  Google Scholar 

  4. Welsh, R, Trowbridge RS, Kowalski JB et al: Amantadine HCI inhibition of early and late stages of lymphocytic choriomeningitis virus cell interaction. Virology 45: 679, 1971

    Article  PubMed  CAS  Google Scholar 

  5. Bleidner, WE, Harmon, JB, Hewes, WE, Lynes, TE, Herman, EC: Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 150:484–490, 1965

    PubMed  CAS  Google Scholar 

  6. Walker, JS, Stephan EL, Spertzel RO: Small particle aerosoles of antiviral compounds in treatment of type A influenza pneumonia in mice. J Infec Dis 133:Suppl A140-A144, 1976

  7. Haydin FG, Hall, WJ, Douglas RG, Jr., et al: (Abstract) Aerosolized amantadine HCI pharmacokinetics and safety testing in normal volunteers. 17th Interscience conference on Antimicrobial Agents and Chemotherapy Oct 1977. Abs 279

  8. Wright PF, Khaw KT, Oxman N, et al: Evaluation of the safety of amantadine HCI and the role of respiratory viral infection in children with cystic fibrosis. J Infect Dis 134:144–149, 1976

    PubMed  CAS  Google Scholar 

  9. Couch RB, Jackson GG: Antiviral agents in influenza: summary of Influenza Workshop VIII. J Infect Dis 134:516–527, 1976

    PubMed  CAS  Google Scholar 

  10. Galbraith AW, Oxford JS, Schild GC, et al: Protective effect of 1-Adamantamine HCI on influenza A2 infections in the family environment. Lancet 2:1026–1028, 1969

    Article  PubMed  CAS  Google Scholar 

  11. Galbraith AW, Oxford JS, Schild, GC, et al: Therapeutic effect of 1-admantamine HCI in naturallv occurring influenza A2 Hong Kong infection. Lancet 2:7714–7726, 1971

    Google Scholar 

  12. Jackson GG: (Editorial) Sensitivity of influenza A virus to amantadine J Infect Dis 136: 2 301–302, 1977

    PubMed  CAS  Google Scholar 

  13. Lamar JK, Calhoun, FJ, Darr AG: Effects of amantadine HCI on cleavage and embryonic development in the rat and rabbit. Toxicol Appl Pharmacol 17:272, 1970

    Article  Google Scholar 

  14. Jackson GG, Muldoon RL, Akers, LW: Serologic evidence for prevention of influenzal infection in volunteers by an anti-influenzal drug, amantadine hydrochloride. Antimicrob Agents Chemother 3:703–707, 1963

    Google Scholar 

  15. Togo Y, Hornick RB, Dawkins AT, Jr: Studies on induced influenza in man. 1. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against A2/Rockville/1/65 strain. JAMA 203:1089–1094, 1968

    Article  PubMed  CAS  Google Scholar 

  16. Quilligan, JJ, Jr, Hiayama M, Baernstein HD, Jr: The suppression of A2 influenza in children by the chemoprophylactic use of amantadine. J Pediatr 69:572–575, 1966

    Article  PubMed  Google Scholar 

  17. Oker-Blom N, Hovi T, Leinikil, P., Palosuo, T, Pettersson, R, Suni, J: Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial. Br Med J 3:676–678, 1970

    PubMed  CAS  Google Scholar 

  18. Smorodintsev AA, Karpuchin GI, Zlydnikov DM, et al: The prospect of amantadine for prevention of influenza A2 in humans: effectiveness of amantadine during Influenza A2/Hong Kong epidemic of January–February, 1969 in Leninngrad. Ann NY Acad Sci 173:44–61, 1970

    Article  Google Scholar 

  19. O’Donoghue JM, Ray CG, Terry DW, JR, Beaty HN: Prevention of nosocomial influenza infection with amantadine. Am J Epidemiol 97:276–282, 1973

    PubMed  CAS  Google Scholar 

  20. Cohen A, Togo Y, Khakoo R, et al: Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine HCI and placebo in induced human influenza type A. J Infect Dis 133 Suppl A 114-A 120, 1976

  21. Mate J, Simon M, Vancz Juvancy I: Use of Viregyt (Amantadine HCI) in the treatment of epidemic influenza. Ther Hung 19:117–121, 1971

    PubMed  CAS  Google Scholar 

  22. Walters HE, Paulshock M: Therapeutic efficacy of mantadine HCI. Missouri Med 67:176–197, 1970

    PubMed  CAS  Google Scholar 

  23. Watson GI: Use of Amantadine in an epidemic of “Hong Kong” influenza type A2 in family practice. Practitioner 205:351–357, 1970

    PubMed  CAS  Google Scholar 

  24. Little JW, Hall WJ, Douglas RG: Small airways dysfunction in influenza virus infection: therapeutic role and potential mode of action of amantadine. Ann NY Acad Sci 284:106–117, 1977

    Article  PubMed  CAS  Google Scholar 

  25. Galbraith AW, Schild GC, Potter CW, et al: The therapeutic effect of amantadine in influenza occurring during the winter of 1971–72 assessed by double blind study. J Roy Coll Gen Pract 23:34–57, 1973

    CAS  Google Scholar 

  26. LaMontagne JR, Galasso GJ: Report of a workshop on clinical studies of the efficacy of amantadine and rimantadine against influenza virus. J Infect Dis 138:928–931, 1978

    PubMed  CAS  Google Scholar 

  27. Knight V, Fedson D, Baldini J, Douglas RG, Couch RB: Amantadine therapy of epidemic influenza A: (Hong Kong). Infect Immun 1:200–204, 1970

    PubMed  CAS  Google Scholar 

  28. Little JW, Hall WJ, Douglas RG: Small airways dysfunction in influenza virus infection: therapeutic role and potential mode of action of amantadine. Ann NY Acad Sci 284:106–117, 1977

    Article  PubMed  CAS  Google Scholar 

  29. Sabin AB: Amantadine and influenza: evaluation of conflicting reports. J Infect Dis 138:557–566, 1978

    PubMed  CAS  Google Scholar 

  30. Arroyo M, Beare AS, Reed SE, et al: A therapeutic study of an adamantane spiro compound in experimental influenza A infection in man. J Antimicrob Chemother 1:87–93, 1975

    PubMed  CAS  Google Scholar 

  31. Beare AS, Hall TS, Ty-rell DAJ: Protection of volunteers against challenge with A/Hong Kong/68 influenza virus by a new amantadine compound. Lancet 1:1039–1040, 1972

    Article  PubMed  CAS  Google Scholar 

  32. Lee WW, Benitez A, Goodman L, Baker BR: Potential anticancer agents. XL. Synthesis of the B-anomer of 9-(D-arabino-furanosyl)-adenine. J Am Chem Soc 82:2648–2649, 1960

    Article  CAS  Google Scholar 

  33. Whitley RJ, Ch’ien LT, Dolin R, Galasso GJ, Alford CA, Jr: collaborative Study Group. Adenine arabinoside therapy of herpes zoster in the immunosuppressed: NIAD Collaborative Antiviral Study. N Engl J Med 294:1193–1199, 1976

    Article  PubMed  CAS  Google Scholar 

  34. Whitley, RJ, Soong SJ, Dolin R, et al: Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis: NIAID Collarborative Antiviral Study. N Engl J Med 297:289–294, 1977

    Article  PubMed  CAS  Google Scholar 

  35. Shannon WM: Adenine arabinoside antiviral activity in vitro. In Pavan-Langston D, Buchanan RA, Alford CA, Jr eds. Adenine arabinoside. antiviral agent. New York: Raven Press, 1–43, 1975

    Google Scholar 

  36. Shipma, C, Jr, Smith SH, Darlson RH, Drach JC: Antiviral activity of arabinosy-ledening and arabinosylhypoxanthine in herpes simplex virusinfected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in synchronized suspension cultures Antimicrob. Agents: Chemother 9:120–127, 1976

    Google Scholar 

  37. Muller WEG: Mechanisms of action and pharmacology: chemical agents. In: Galasso GJ, Merigan TC, Buchanan RA, eds. Antiviral agents and viral diseases on man. New York: Raven Press, 77–149, 1979

    Google Scholar 

  38. Muller WEG: Mechanisms of action and pharmacology: chemical agents In: Galasso GJ, Merigan TC, Buchanan RA, eds. Antiviral agents and viral diseases of man. New York: Raven Press, 77–149, 1979

    Google Scholar 

  39. Bryson Y, Connor SD, Sweetman L, et al: Determination of plaque inhibitory activity of adenine arabenoside for herpesvirus using an adenosine deaminase inhibitor. antimicrob Agent Chemother 6:98–101, 1974

    CAS  Google Scholar 

  40. Bryson YJ, Kroneberg LH: Combined antiviral effects of interferon, adenine arabinoside, hydroxanthine arabinoside and adenine arabinoside 5′ monophosphate in human fibroblast cultures. Antimicrob Agents Chemother 11: 99–306, 1977

    Google Scholar 

  41. Lerner AM, Baily EJ: Synergy of 9-β Darabinofuranosyladenine and human interferon against Herpes simplex virus type 1. J Infec Dis 130:549–552, 1974

    CAS  Google Scholar 

  42. Sidwell RW, Allen LB, Huffman JH, Khwaja TA, Tolman RL, Robins RK: Anti-DNA birus activity of the 5′-nucleotide and 3′, 5′-cyclic nucleotide of 9-β-D-arabinofuranosylandenine. Chemotherapy 19:325–340, 1973

    Article  PubMed  CAS  Google Scholar 

  43. Ross AH, Antonio, Julia, and Balakrishnan CH: Toxicity of adenine arabinoside in humans. J Infec Dis 133 Suppl. A192-A198 1976

  44. Bodey GP, Gottlieb J, McCredie KB, Freireich EJ: Adenine arabinoside in cancer chemotherapy. In: Pavan-Langstone D, Buchanan RA, Alford CA, Jr. eds. Adenine arabinoside: an antiviral agent: New York: Raven Press, 281–285, 1975

    Google Scholar 

  45. Lauter CB, Bailey EJ, Lerner AM: Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans. J Infect Dis 134:75–79, 1976

    PubMed  CAS  Google Scholar 

  46. Whitley RJ, Chien LT, Nahmias AJ, et al: Adenne arabinoside therapy of neonatal herpetic infections. In: Pavan Langston D. (Ed.): Adenine arabinoside antiviral agent. NY Raven Press 1975

  47. Abel R, Jr, Kaufman HE, Sugar J: Intravenous adenine arabinoside against herpes simplex Keratouveitis in humans. Am J Opthal 79:659–664, 1975

    Google Scholar 

  48. Kraemer KG, Neiman PE, Reeves WC, Thomas ED: Prophylactic adenine arabinoside following marrow transplantation. Transpeant Proc 10:237–240, 1978

    CAS  Google Scholar 

  49. Ch’ien LT, Cannon NJ, Whitley RJ, et al: Effect of adenine arabinoside on cytomegalovirus infections. J Infect Dis 130:32–9, 1974

    PubMed  CAS  Google Scholar 

  50. Rytel MW, Kauffman MH: Clinical efficacy of adenine arabinoside in therapy of CMV infections in renal allograft recipients. J Infect Dis 133:2 202–205, 1976

    PubMed  CAS  Google Scholar 

  51. Polard RB, Smith JL, Neal EA, et al: Effect of vidarabine on chronic hepatitis B virus infection. JAMA 239:1648–1650, 1978

    Article  Google Scholar 

  52. Pavan-Langston D: Clinical evaluation of adenine arabinoside and idoxuridine in the treatment of ocular herpes simplex. Am J Ophthalmol 80:495–502, 1975

    PubMed  CAS  Google Scholar 

  53. Paven-Langston D: Clinical evaluation of adenine arabinoside and idoxuridine in the treatment of ocular herpes simplex. Am J Ophthalmol 80:495–502, 1975

    Google Scholar 

  54. O’Day DM, Poirer RH, Jones DB, Elliot JH: Vidarabine therapy of complicated herpes simplex keratitis. Am J Ophthalmol 81:642–649, 1976

    PubMed  CAS  Google Scholar 

  55. Spruance SL, a Crupacker CS, Haines H, et al: Inffectiveness of topical adenine arabinoside 5′-monophosphate in the treatment of recurrent herpes simplex labialis. N Engl J Med 300:1180–1184, 1979

    Article  PubMed  CAS  Google Scholar 

  56. Goodman EL, Luby JP, Johnson MT: prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis. Antimicrob Agents Chemother 8:693–697, 1975

    PubMed  CAS  Google Scholar 

  57. Adams HG, Benson EA, Alexander ER, Vontver LA, Remington MA, Holmes KK: Genital herpetic infection in men and women: Clinical course and effect of topical application of adenine arabinoside. J Infect Dis 133A: 151–159, 1976

    Google Scholar 

  58. Crumpacker CS, Schnipper LE, Zaia JA, Levin MJ: Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother 15:642–645, 1979

    PubMed  CAS  Google Scholar 

  59. Schaeffer HJ, Beauchamp L, de Miranda, P, Elion GB, Bauer DJ, Collins P: 9- (2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272:583–585, 1978

    Article  PubMed  CAS  Google Scholar 

  60. Colby B, Shaw J, Elion G, Pagano JS: The effect of acyclovir (9-(2-hydroxy-yethorymethyl) guanine) on Epstein-Barr virus DNA replication. J Virol (in press)

  61. Selby PJ, Powles RL, Jameson B, et al: Parenteral acyclovir therapy for herpesvirus infections in man. Lancet 2:1267–1270, 1979

    Article  PubMed  CAS  Google Scholar 

  62. Field HJ, Bell SE, Elion GB, Nash AA, Wildy P: Effect of acycloguanosine treatment on acute and latent herpes simplex infection in mice. Antimicrob Agents Chemother 15:554–561, 1979

    PubMed  CAS  Google Scholar 

  63. Jones BR, Coster DJ, Fison PN, Cobo LM, Falcon MG: Efficacy of acycloguanosine (Wellcome 248 U) against herpes simplex corneal ulcers. Lancet 1:243–244, 1979

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics and Microbiology, School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA

    Sarah Bogger-Goren M.D. & Pearay L. Ogra M.D. (Professor of Pediatrics and Microbiology)

Authors
  1. Sarah Bogger-Goren M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pearay L. Ogra M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bogger-Goren, S., Ogra, P.L. Antiviral agents: An update—Part I. Indian J Pediatr 47, 431–440 (1980). https://doi.org/10.1007/BF02759848

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02759848

Keywords

Search

Navigation